Novo Nordisk A/S


Download Data

Novo Nordisk A/S Market Capitalization on April 17, 2024: USD 564.13 B

Novo Nordisk A/S Market Capitalization is USD 564.13 B on April 17, 2024, a 51.65% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.
  • Novo Nordisk A/S 52-week high Market Capitalization is USD 604.85 B on March 12, 2024, which is 7.22% above the current Market Capitalization.
  • Novo Nordisk A/S 52-week low Market Capitalization is USD 333.62 B on July 11, 2023, which is -40.86% below the current Market Capitalization.
  • Novo Nordisk A/S average Market Capitalization for the last 52 weeks is USD 434.17 B.

Novo Nordisk A/S

CEO Mr. Lars Fruergaard Jorgensen
IPO Date Jan. 4, 1982
Location Denmark
Headquarters Novo Allé 1, Bagsvaerd, Denmark, 2880
Employees 63,370
Sector Healthcare
Industry Biotechnology

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Similar companies


Regeneron Pharmaceuticals Inc

USD 894.14



CureVac NV

USD 2.67



BioNTech SE

USD 86.34



Hepion Pharmaceuticals Inc

USD 2.04


StockViz Staff

April 18, 2024

Any question? Send us an email